The combination of axi-cel and rituximab showed high efficacy in refractory LBCL, with a 73% complete response rate and 88% overall response rate. Safety was favorable, with no new signals; 96% ...
In July 2025, a class 2 resubmission of tab-cel’s BLA was initiated by Atara Biotherapeutics, developer and sponsor of ...
This three-year agreement provides AbbVie with exemption from tariffs and future pricing mandates, the company said, ...
The U.S. Food and Drug Administration declined to approve Atara Biotherapeutics' cell therapy for a rare form of blood ...
The 2025 American Society of Hematology (ASH) meeting in December presented a clear message: scientific innovation and ...
SaveHealth reports on common rheumatoid arthritis medications, highlighting their effectiveness, side effects, and cost ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback